Skip to main content
. 2019 Jul 26;70(12):2663–2672. doi: 10.1093/cid/ciz704

Table 3.

Frequency of Adverse Infant Outcomes by Zika Virus Infant Groups

NSNM Proportional Microcephaly Disproportional Microcephaly SGA Odds Ratioa,b (95% Confidence Interval); P Value for SGA vs NSNM Groups
Type of Infant Outcome n = 116 n = 13 n = 13 n = 14 P Value
NICU (days) 2.1 (4.7) 21.8 (30.0) 9.8 (11.9) 28.8 (78.9) <.001
Mean (standard deviation) rangec (0 –30) (0–100) (0–47) (0–300)
Median (interquartile range) 0 (0 –0) 4.0 (0 –35.0) 8.0 (5.0–10.0) 0 (0.0–18.0)
NICU stay
Yes 25 (21.7%) 7 (53.9%) 10 (76.9%) 6 (42.9%) <.001
No 90 (78.3%) 6 (46.2%) 3 (23.1%) 8 (57.1%)
TFUS
Abnormal 5 (5.0%) 11 (100%) 11 (100%) 5 (35.7%) <.001
Normal 106 (95.0%) 0 (0%) 0 (0%) 9 (64.3%)
Head CT scan
Abnormal 7 (63.6 %) 13 (100%) 13 (100%) 5 (83.3%) .010
Normal 4 (36.4%) 0 (0%) 0 (0%) 1 (16.7%)
Head MRI scan
Abnormal 18 (60%) 4 (100%) 9 (100%) 1 (50%) .056
Normal 12 (40%) 0 (0%) 0 (0%) 1 (50%)
Ophthalmologic exam
Abnormal 6 (5.2%) 10 (77.9%) 9 (69.2%) 4 (28.6%) <.001
Normal 109 (94.8%) 3 (23.1%) 4 (30.8%) 10 (71.4%)
Hearing exam
Abnormal 2 (1.9%) 4 (33.3%) 3 (23.1%) 1 (7.7%) <.001
Normal 103 (98.1%) 8 (66.7%) 10 (76.9%) 12 (92.3%)
Morphologic evaluation
Abnormal 4 (3.5%) 13 (100%) 13 (100%) 4 (28.6%) <.001
Normal 112 (96.5%) 0 (0%) 0 (0%) 10 (71.4%)
Neurologic evaluation
Abnormal 13 (11.2%) 13 (100%) 13 (100%) 6 (42.9%) <.001
Normal 103 (88.8%) 0 (0%) 0 (0%) 8 (57.1%)
Infectionsd
Yes 43 (37.1%) 6 (46.2%) 1 (7.7%) 2 (14.3%) .045
No 73 (62.9%) 7 (53.8%) 12 (92.3%) 12 (85.7%)
Seizures
Yes 5 (4.3%) 11 (84.6%) 11 (84.6%) 3 (21.4%) <.001
No 111 (95.7%) 2 (15.4%) 2 (15.4%) 11 (78.6%)
Dysphagia
Yes 2 (1.7%) 7 (53.8%) 5 (38.5%) 2 (14.4%) <.001
No 114 (98.3%) 6 (46.2%) 8 (61.5%) 12 (85.7%)
Gastrostomy tube
Yes 0 (0%) 2 (15.4%) 1 (7.7%) 2 (14.3%) .001
No 116 (100%) 11 (84.6%) 12 (92.3%) 12 (85.7%)
Ventriculoperitoneal shunt
Yes 2 (1.7%) 1 (7.7%) 1 (7.7%) 2 (14.3%) .051
No 114 (98.3%) 12 (92.3%) 12 (92.3%) 12 (85.7%)
Grouped infant outcomes
Any abnormal neuroimaging (TFUS, head CT, head MRI)
Yes 17 (16.0%) 13 (100%) 13 (100%) 6 (42.9%) <.001 3.9 (1.2–12.8)e; P = .023
No 89 (84.0%) 0 (0%) 0 (0%) 8 (57.1%)
Any abnormal ophthalmologic, hearing, or neurologic exam
Yes 21(18.3%) 13 (100%) 13 (100%) 6 (42.9%) <.001 3.4 (1.1–10.7)e; P = .041
No 94 (81.7%) 0 (0%) 0 (0%) 8 (57.1%)
Any abnormality except NICU stay or infection
Yes 33 (28.5%) 13 (100%) 13 (100%) 6 (42.9%) <.001 1.9 (0.6–5.9)e; P = .272
No 83(71.5%) 0 (0%) 0 (0%) 8 (57.1%)

Abbreviations: CT, computed tomography; MRI, magnetic resonance imaging; NICU, neonatal intensive care unit; NSNM, neither SGA nor microcephaly; SGA, small for gestational age; TFUS, transfontanelle ultrasound.

aOdds ratio (OR) comparing SGA and NSNM groups only (reference group NSNM).

bRefer to Supplementary Table 3 for multivariate logistic regression with adjusted ORs for grouped infant outcomes shown above adjusted for infant gender, prematurity, maternal health and pregnancy issues, and infection.

cPlease note that regarding NICU stay (days) for the SGA group, mean length of stay (days) was longest because 1 SGA infant with congenital Zika syndrome was never discharged from the hospital following 300 days. Further details are available in Supplementary Table 2 for infant 3.

dInfections (including pneumonias, urinary tract infections, skin infections, and bronchiolitis) among Zika virus–exposed infants primarily occurred beyond the immediate postnatal period during follow-up.

eFischer exact test was performed to determine P values comparing the 4 infant groups.